Author

A. Witkiewicz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

E. Knudsen· 3 shared J. Wang· 2 shared P. Vail· 2 shared V. Kumarasamy· 2 shared A. Dynka· 1 shared A. Grant· 1 shared A. Ruiz· 1 shared C. Frangou· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Knudsen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Pharmacologically targeting KRASG12D in PDAC models:tumor cell intrinsic and extrinsic impact

V. Kumarasamy, C. Frangou, J. Wang, Y. Wan, A. Dynka, H. Rosenheck, P. Dey, E. V. Abel, E. Knudsen, A. Witkiewicz

This study evaluates KRASG12D inhibition in PDAC models, showing variable efficacy in 2D cultures but enhanced response in 3D cultures and xenografts, with immunological modulation contributing to tumor regression.

bioRxiv · Mar 18, 2023Cancer Biology

Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer

E. Knudsen, V. Kumarasamy, S. Chung, P. Vail, S. Tzetzo, A. Ruiz, M. Seshadri, S. Abrams, J. Wang, A. Witkiewicz

This study shows that combining MEK and CDK4/6 inhibitors with immune checkpoint inhibitors improves pancreatic cancer treatment by enhancing T-cell infiltration and altering myeloid populations in preclinical models.

bioRxiv · Dec 5, 2019Cancer Biology

Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations

A. Grant, P. Vail, M. Padi, A. Witkiewicz, E. Knudsen

The paper introduces MAXX, a tool to analyze allelic expression of mutations in cancer, identifying driver mutations and prognostic subtypes in PDAC.

bioRxiv · Aug 17, 2018Cancer Biology